Cara Therapeutics | CARA - Ebit


Cara Therapeutics reported $-5.94M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cassava Sciences USD -13.55M 1.69M Dec/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
CSL USD 2.64B 116M Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
J&J USD 6.62B 1.51B Mar/2026
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.65B 71M Dec/2025
RedHill Biopharma USD 2.69M 47.97M Jun/2023
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024